EMulate Therapeutics, Inc. (EMTX)

EMulate Therapeutics was planning to go public, but the IPO was withdrawn on Jul 31, 2024.

IPO Price Range

$4.00 - $6.00

Shares Offered

2,300,000

Deal Size

$11.50M

EMulate Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2021	FY 2020
Period Ending	Jun '22 Jun 30, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	0.26	0.24	0.11
Revenue Growth	-	113.27%	-
Gross Profit	0.26	0.24	0.11
Operating Income	-15.97	-11.33	-10.64
Net Income	-28.02	-22.09	3.46

Fiscal Year	Current	FY 2021	FY 2020
Period Ending	Jun '22 Jun 30, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Investments	0.01	0.35	0.12
Total Debt	10.21	9.3	7.07
Net Cash (Debt)	-10.2	-8.95	-6.95
Net Cash Growth	-	-	-

Fiscal Year	TTM	FY 2021	FY 2020
Period Ending	Jun '22 Jun 30, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Cash Flow	-3.87	-3.32	-4.02
Free Cash Flow	-3.88	-3.32	-4.02
Free Cash Flow Growth	-	-	-

Fiscal Year	TTM	FY 2021	FY 2020
Period Ending	Jun '22 Jun 30, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-6264.31%	-4700.41%	-9412.39%
Pretax Margin	-10989.41%	-9166.80%	3059.29%
Profit Margin	-10989.41%	-9166.81%	3059.29%
FCF Margin	-1520.39%	-1378.42%	-3555.75%